Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Raw Materials (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Raw Materials data on record, last reported at $2.9 million in Q4 2025.

  • For Q4 2025, Raw Materials fell 4.36% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, down 4.36%, while the annual FY2025 figure was $2.9 million, 4.36% down from the prior year.
  • Raw Materials reached $2.9 million in Q4 2025 per MIRM's latest filing, up from $2.9 million in the prior quarter.
  • Across five years, Raw Materials topped out at $3.0 million in Q4 2024 and bottomed at $444000.0 in Q3 2023.
  • Average Raw Materials over 5 years is $2.4 million, with a median of $2.9 million recorded in 2024.
  • Peak YoY movement for Raw Materials: skyrocketed 528.38% in 2024, then decreased 4.36% in 2025.
  • A 5-year view of Raw Materials shows it stood at $856000.0 in 2021, then increased by 0.23% to $858000.0 in 2022, then surged by 249.42% to $3.0 million in 2023, then rose by 1.07% to $3.0 million in 2024, then decreased by 4.36% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $2.9 million in Q4 2025, $2.9 million in Q3 2025, and $2.9 million in Q2 2025.